On June 16, 2021 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, reported that the Data and Safety Monitoring Board recommended the Company proceed to the eighth cohort of the Phase 1 dose escalation ReSPECT trial, which is evaluating the Company’s lead investigational drug, Rhenium NanoLiposome (RNL), in patients with recurrent glioblastoma (GBM)(Press release, Cytori Therapeutics, JUN 16, 2021, View Source [SID1234584066]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased with the favorable safety profile observed thus far with RNL in recurrent GBM," said Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. "Moving to cohort eight will allow us to continue to push the envelope in terms of addressable tumor size and maximum radiation dose delivered."
Twenty-one patients with recurrent GBM have been treated in the ReSPECT trial across seven cohorts to date. In these patients, RNL has had no dose-limiting toxicities observed with absorbed radiation doses of up to 740 Gray per tumor.
The eighth cohort of the ReSPECT trial will implement a 40% increase in total radioactivity. The planned infused dose will be 31.2 millicuries in a volume of 12.3 milliliters (increased from 22.3 millicuries and 8.8 milliliters, respectively, used in cohort seven). The planned maximum flow rate will not change.
RNL is under investigation as a potentially safe, effective and convenient way to deliver a very high dose of radiation, possibly over 20 times greater than traditional external beam radiation therapy. This trial is supported by the U.S. National Institutes of Health/National Cancer Institute at three trial sites in the U.S., including UT Health Science Center San Antonio, UT Southwestern Medical Center and UT MD Anderson Cancer Center Houston.
The U.S. Food and Drug Administration has granted both Orphan Drug designation and Fast Track designation to RNL for the treatment of patients with GBM. Additional details about the ReSPECT trial are available at clinicaltrials.gov (NCT01906385).
The latest corporate information can be found on the Company’s Investor Relations page at ir.plustherapeutics.com/presentations.